Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video

Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video - ACCME

Activity Description

Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.

Accreditation Statement

The Fundingsland Group is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Fundingsland Group, LLC designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: 05-29-2026
Expiration Date: 05-28-2027

Target Audience

This accredited educational activity is designed for ophthalmologists.

Grant Support Statement

This activity is supported by an unrestricted educational grant from AbbVie.

Faculty

Kaleb Abbott, OD

Neel Pasricha headshot

Neel Pasricha, MD

1 - Introduction - Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video - ACCME
2 - Activity - Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video - ACCME
3 - Evaluation - Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video - ACCME

Progress